The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

@article{Ives2002TheHM,
  title={The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.},
  author={Jane A L Ives and John Austin Carr and Dirk B. Mendel and Chun Y Tai and Robert Lambkin and Leanne Kelly and John S. Oxford and Frederick G. Hayden and Noel A. Roberts},
  journal={Antiviral research},
  year={2002},
  volume={55 2},
  pages={307-17}
}
Oseltamivir carboxylate is a potent and specific inhibitor of influenza A and B neuraminidase (NA). Oseltamivir phosphate, the ethyl ester prodrug of oseltamivir carboxylate, is the first orally active NA inhibitor available for the prophylaxis and treatment of influenza A and B. It offers an improvement over amantadine and rimantadine which are active only against influenza A and rapidly generate resistant virus. The emergence of virus resistant to oseltamivir carboxylate in the treatment of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 153 extracted citations

Similar Papers

Loading similar papers…